All In MedTech

Device Trial Radar · NCT04139564

EaseVRx for the Reduction of Chronic Pain and Opioid Use

Safety and Effectiveness of Virtual Reality Utilizing EaseVRx for the Reduction of Chronic Pain and Opioid Use

Last checked: Nov 19, 2026Latest source record: Mar 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

108

Actual

Start

Jan 11, 2021

Primary completion

Aug 31, 2022

Study completion Aug 31, 2022

Sponsor

Lead sponsor
AppliedVR Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Geisinger Clinic; National Institute on Drug Abuse (NIDA)
First posted
Oct 25, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EaseVRx, a software-based virtual reality (VR) medical device, is intended to offer users a prescription pain management tool that manages the symptoms associated with chronic pain and reduces or eliminates the risk of opioid dependence. The investigators will conduct a proof-of-concept randomized study to assess the feasibility and efficacy of using EaseVRx as a 56-day, VR-based, at-home program among 100 chronic low back pain patients by gathering pilot data on the efficacy of the intervention in decreasing pain, reducing opioid/non-opioid pharmacotherapy, and improving pain-related quality of life.

Conditions

  • Chronic Low-back Pain

Interventions

  • EaseVRx headsetDevice

    EaseVRx is a virtual reality therapy intended to treat chronic pain

  • Active control VR sham programDevice

    VR, 2d visual wildlife scenes similar to some EaseVRx content

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain: Numerical Pain Rating ScaleTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Geisinger Medical Center

    Danville, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.